Conformationally restricted GABA analogs: From rigid carbocycles to cage hydrocarbons

Future Medicinal Chemistry

Volumn 3, Issue 2, 2011, Pages 223-241

  Levandovskiy, Igor A ^a   Sharapa, Dmitry I ^a   Shamota, Tatyana V ^a   Rodionov, Vladimir N ^a   Shubina, Tatyana E ^b  

^a NATIONAL TECHNICAL UNIVERSITY OF UKRAINE   (Ukraine)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOMETHYLCYCLOPROPANE 1 CARBOXYLIC ACID; 3 AMINOCYCLOBUTANE CARBOXYLIC ACID; 3 AMINOCYCLOPENTANECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID DERIVATIVE; ADAMANTANE; BICYLCO[3.3.1]NONANE; CYCLOBUTANE; CYCLOHEXANE; CYCLOPROPANE; GABAPENTIN; HYDROCARBON; NORBORNANE; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; ANTINOCICEPTION; ANXIETY DISORDER; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CHEMICAL BOND; CIS TRANS ISOMERISM; DIABETIC NEUROPATHY; DRUG ACTIVITY; DRUG BINDING; DRUG CONFORMATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; EPILEPSY; HUMAN; LIPOPHILICITY; NEUROPATHIC PAIN; NONHUMAN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RESTLESS LEGS SYNDROME; REVIEW; STRUCTURE ACTIVITY RELATION;

ADAMANTANE; AMINES; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HYDROCARBONS, CYCLIC; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79951588185     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.287     Document Type: Review

References (74)

1. Roberts E, Frankel S. γ-aminobutyric acid in brain: its formation from glutamic acid. J. Biol. Chem. 187, 55-63 (1950).
2. Boistel J, Fatt P. Membrane permeability change during inhibitory transmitter action in crustacean muscle. J. Physiol. (Lond.) 144, 176-191 (1958).
3. Coombs JS, Eccles JC, Fatt P. The specific ionic conductances and the ionic movements across the motoneuronal membrane that produce the inhibitory postsynaptic potential. J. Physiol. (Lond.) 130, 326-373 (1955).
4. Krnjevic K, Schwartz S. The action of γ-aminobutyric acid on cortical neurones. Exp. Brain Res. 3, 320-336 (1967).
5. Nicholson SH, Suckling CJ, Iversen LL. GABA analogues: conformational analysis of effects on [3H]GABA binding to postsynaptic receptors in human cerebellum. J. Neurochem. 32, 249-252 (1979). (Pubitemid 9108959)
6. Johnston GAR, Curtis DR, Beart PM, Game CJA, Mcculloch RM, Twitchin B. Cis- and trans-4-aminocrotonic acid as GABA analogues of restricted conformation. J. Neurochem. 24, 157-160 (1975).
7. Segal M, Sims K, Andsmissman E. Characterisation of an inhibitory receptor in rat hippocampus: a microiontophoretic study using conformationally restricted amino acid analogues. Br. J. Pharmacol. 54, 181-188 (1975).
8. Johnston GAR, Allan RD, Kennedy SME, Twitchin B. A systematic study of GABA analogues of restricted conformation. In:GABA-Neurotransmitters . Kofod H, Krogsgaard-Larsen P, Scheel-Kruger J (Eds). Munksgaard, Copenhagen, Denmark 149-164 (1978).
9. Krogsgaard-Larsen P, Johnston GAR, Lodge D, Curtis DR. A new class of GABA agonist. Nature 268, 53-55 (1977). (Pubitemid 8136628)
10. Krogsgaard-Larsen P, Johnston GAR, Curtis DR, Game CJA, Mcculloch RM. Structure and biological activity of a series of conformationalty restricted analogues of GABA. J. Neurochem. 25, 803-809 (1975).
11. Allan RD, Curtis DR, Headley P, Johnson DR, Lodge D, Twitchin B. The synthesis and activity of cis-and trans-2- (aminomethyl) cyclopropanecarboxylic acid as conformationally restricted analogues of GABA. J. Neurochem. 34(3), 652-654 (1980). (Pubitemid 10165083)
12. Paulini K, Reissig H-U. Ein effektiver Weg zu GABA-analogen Aminosauren: Cyclopropanierung von N-silylierten Allylaminen und Enaminen. Liebigs Ann. Chem. 455-461 (1991).
13. Galeazzi R, Mobbili G, Orena M. From 3-aza-2-oxobicyclo[3.1.0]hexane to enantiopure disubstituted cyclopropane: a convenient approach to cis-2,3-methano- GABA. Tetrahedron. Asymm. 8(1), 133-137 (1997). (Pubitemid 27039333)
14. Galeazzi R, Mobbili G, Orena M. A convenient approach to diastereomerically pure 1,3,4-trisubstituted pyrrolidin-2-ones by intramolecular cyclisation of N-(2-alken-1-yl) amides mediated by Mn(III). An entry to both (R)- and (S)-3-pyrrolidineacetic acid. Tetrahedron 52, 1069-1084 (1996).
15. Rodríguez-Soria V, Quintero L, Sartillo-Piscil F. A novel stereoselective tin-free radical protocol for the enantioselective synthesis of pyrrolidinones and its application to the synthesis of biologically active GABA-derivatives. Tetrahedron 64, 2750-2754 (2008).
16. Duke RK, Allan RD, Chebib M, Greenwood JR, Johnson DR. Resolution and conformational analysis of diastereoisomeric esters of cis- and trans-2-(aminomethyl)-1- carboxycyclopropanes. Tetrahedron Assym. 9, 2533-2548 (1998). (Pubitemid 28374948)
17. Duke RK, Chebib M, Balcar VJ, Allan RD, Mewett KN, Johnson GAR. (+)- and (-)-cis-2-aminomethylcyclopropanecarboxylic acids show opposite pharmacology at recombinant r1 and r2 GABAC receptors. J. Neurochem. 75(6), 2602-2610 (2000).
18. Allan RD, Curtis R, Headley PM et al. Cyclobutane analogs of GABA. Neurochem. Res. 5(4), 393-400 (1980). (Pubitemid 10109854)
19. Baxendale IR, Ernst M, Krahnert W-R, Ley SV. Application of polymer-supported enzymes and reagents in the synthesis of γ-aminobutyric acid (GABA) analogues. Synlett 10, 1641-1644 (2002). (Pubitemid 35190739)
20. Chenevert R, Martin R. Enantioselective synthesis of (+) and (-)-cis-3-aminocyclo-pentanecarboxylic acids by enzymatic asymmetrization. Tetrahedron Asymm. 3, 199-200 (1992).
21. Allan RD, Johnson DR, Twitchin B. Synthesis of analogues of GABA. III. All four stereo-isomers of 3-aminocyclo-pentanecarboxylicacid and a stereochemical correlation with amidinomycin. Aust. J. Chem. 32, 2517-2521 (1979). (Pubitemid 10077753)
22. Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the a2d subunit of a calcium channel. J. Biol. Chem. 271, 5768-5776 (1996). (Pubitemid 26083915)
23. Stahl S. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as a2d ligands at voltage-gated calcium channels. J. Clin. Psychiatry 65, 596-597 (2004).
24. Taylor CP, Gee NS, Su T-Z et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29, 233-249 (1998). (Pubitemid 28137601)
25. McLean M. Gabapentin in the management of convulsive disorders. Epilepsia 40 (Suppl. 6), S39-S50 (1999). (Pubitemid 29481921)
26. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J. Am. Med. Assoc. 280, 1837-1842 (1998). (Pubitemid 28544424)
27. Rice A, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94, 215-224 (2001). (Pubitemid 33016615)
28. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59, 1573-1579 (2002). (Pubitemid 35387065)
29. Pollack M, Matthews J, Scott E. Gabapentin as a potential treatment for anxiety disorders. Am. J. Psychiatry 155, 992-993 (1998). (Pubitemid 28307619)
30. Backonja M, Beydoun A, Edwards K et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J. Am. Med. Assoc. 280, 1831-1836 (1998). (Pubitemid 28544423)
31. McLean M. Gabapentin. Epilepsia 36 (Suppl. 2), S73-S86 (1995).
32. Gidal B, Radulovic L, Kruger S, Rutecki P, Pitterle M, Bockbrader H. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 40, 123-127 (2000). (Pubitemid 30339403)
33. Boyd R, Turck D, Abel R, Sedman A, Bockbrader H. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40, 474-479 (1999). (Pubitemid 29164860)
34. Gidal B, DeCerce J, Bockbrader H et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31(2), 91-99 (1998). (Pubitemid 28361756)
35. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. 19(2), 149-177 (1999). (Pubitemid 29124983)
36. Griffiths G, Mettler H, Mills L, Previdoli F. Novel syntheses of gabapentin via addition of hydrocyanic acid to cyclohexylidenemalonate or cyano(cyclohexylidene)acetate. Helv. Chim. Acta 74, 309-314 (1991).
37. Bryans JS, Horwell DC, Ratcliffe GS, Receveur J-M, Rubin JR. An in vitro investigation into conformational aspects of gabapentin. Bioorg. Med. Chem. 7, 715-721 (1999). (Pubitemid 29238066)
38. Bryans JS, Davies N, Gee NS et al. Identification of novel ligands for the gabapentin binding site on the a2d subunit of a calcium channel and their evaluation as anticonvulsant agents. J. Med. Chem. 41(11), 1838-1845 (1998). (Pubitemid 28248659)
39. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9(3), 275-308 (2003). (Pubitemid 37254706)
40. Germane SK, Polis YY, Karinya LY. Action of midantane, remantadine, and its alkyl analogs on the central nervous system. Pharmaceut. Chem. J. 11(6), 798-802 (1977).
41. Berzinya DA, Kimenis AA. Influence of adapromin on the content of catecholamines in the body of white rats. Exp. Clin. Farmacoterapia 15, 50-53 (1986).
42. Krapivin SV, Sergeeva SA. Comparative analysis of the effects of adapromine, midantane, and bromantane on bioelectrical activity of rat brain. Bull. Exp. Biol. Med. 125(2), 151-155 (1998). (Pubitemid 128695359)
43. Kamianov I, Andrezinia RA. The antiparkinson activity of gludantan (preliminary report). Zh Nevropatol Psikhiatr Im. S.S.Korsakova 75(6), 910-916 (1975).
44. Liubimov BI, Skoldinov AP, Boiko SS. Pharmacokinetic study of 2-(N-benzylamino) adamatane (bemantan) by a gas-liquid chromatographic method. Farmakol. Toksikol. 43(4), 408-411 (1980).
45. Boiko SS, Zherdev VP, Kisliak NA. Interspecific differences in kemantan pharmacokinetics. Farmakol. Toksikol. 1991(54), 1 (1991).
46. Molecular Building Blocks for Nanotechnology. Mansoori GA, George TF, Assoufid L, Zhang G (Eds). Springer, NY, USA (2007).
47. Eaton PE. Synthesis of specific polynitrocubanes. In: Scholarly Research in Explosive Research & Characterization. Geo-Centers Inc., MA, USA, 22 (1993).
48. Taylor BN. Unusual solid state properties of cubane discovered. J. Res. NIST 102(5), 600 (1997).
49. Bashir-Hashemi A. Cubanes: super explosives and potential pharmaceutical intermediates. NASA, Washington, Technology 2003; The Fourth National Technology Transfer Conference and Exposition 1, 127-130 (2003).
50. Bashir-Hashemi A. Chemistry and structure of phenylcubanes. J. Org. Chem. 55(2), 416-420 (1990).
51. Levandovsky IA, Sharapa DI, Cherenkova OA, Gaidai AV, Shubina TE. The chemistry of D3-trishomocubane. Russ. Chem. Rev. 79(11), 1089 (2010).
52. Geldenhuys WJ, Malan SF, Marchand AP. Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med. Res. Rev. 25(1), 21-48 (2005). (Pubitemid 39628525)
53. Liu X, Nuwayhid S, Christie MJ, Kassiou M, Werling LL. Trishomocubanes: novel s ligands modulate amphetamine-stimulated [3H]dopamine release. Eur. J. Pharmacol. 422, 39-45 (2001). (Pubitemid 32595572)
54. Wilcox C Jr, Leung C. Preparation of 4-substituted-bicyclo[2.2.1]heptane- 1- carboxylic acids. J. Org. Chem. 33(2), 877-880 (1968).
55. Davies WL, Grunert RR, Haff RF et al. Antiviral activity of 1-adamantanamine (amantadine). Science 144, 862-863 (1964).
56. Stanicova J, Miskovsky P, Sutiak V. Amantadine: anantiviral and antiparkinsonian agent. Vet. Med. Czech 46, 224-256 (2001).
57. Younossi ZM, Perrillo RP. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin. Liver Dis. 19(Suppl. 1), 662-668 (1999).
58. Smith JP, Riley TR, Devenyi A, Bingaman SI, Kunselman A. Amantadine therapy for chronic hepatitis C. J. Gen. Intern. Med. 19, 662-668 (2004).
59. Galbraith AW. Prevention of post-herpetic neuralgia by amantadine hydrochloride (Symmetrel). Br. J. Clin. Pract. 37, 304-306 (1983). (Pubitemid 13050288)
60. Thompson M, Bones M. Nontraditional analgesics for the management of postherpetic neuralgia. Clin. Pharm. 4, 170-176 (1985). (Pubitemid 15143687)
61. Van der Schyf CJ, Geldenhuys WJ. Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs? Neurotherapeutics 6(1), 175 (2009).
62. Black RM. Synthesis of the four stereoisomers of 4-aminoadamantane-2- carboxylic acid, rigid analogues of γ-aminobutyric acid. J. Chem. Soc. Perkin Trans. 1, 73-77 (1982).
63. Stepanov FN, Srebrodol'skii YI. Acid hydrolysis of acylamido derivatives of adamantane. Vestnik Kievskogo Politekhnicheskogo Instituta 2, 6-10 (1966).
64. Wanka L, Cabrele C, Vanejews M, Schreiner PR. g-aminoadamantanecarboxylic acids through direct C-H bond amidations. Eur. J. Org. Chem. 2007(9), 1474-1490 (2007).
65. Olah GA, Gupta GB, Narang SC. Synthetic methods and reactions; 661. nitrosonium ion induced preparation of amides from alkyl (arylalkyl) halides with nitriles, a mild and selective ritter-type reaction. Synthesis 274-276 (1979).
66. Schreiner PR, Lauenstein O, Kolomitsin IV, Nadi S, Fokin AA. Selective C-H activation of aliphatic hydrocarbons under phase-transfer conditions. Angew. Chem. Int. Ed. 37, 1895-1897 (1998). (Pubitemid 28397799)
67. Schreiner PR, Lauenstein O, Butova ED et al. Selective radical reactions in multiphase systems: phase-transfer halogenations of alkanes. Chem. Eur. J. 7, 4996-5003 (2001). (Pubitemid 34555629)
68. Zoidis G, Papanastasiou I, Dotsikas I et al. The novel GABA adamantane derivative (AdGABA): design, synthesis, and activity relationship with gabapentin. Bioorg. Med. Chem. 13, 2791-2798 (2005). (Pubitemid 40387489)
69. Lanneau C, Green A, Hirst WD et al. Gabapentin is not a GABAB receptor agonist. Neuropharmacology 41(8), 965-975 (2001). (Pubitemid 34024992)
70. Hartenstein J, Satzinger G, Herrmann M. German Patent 2626467 (1977).
71. Satzinger G, Hartenstein J, Herrmann M. German Patent 2543821 (1977).
72. Jennings R, Johnson D, Seamans R, Zeller J. US5319135 (1994).
73. Ferrari M, Ghezzi M, Belotti P. US6846950 (2005).
74. Geigy JR. NL6600715 (1966).